dc.contributor.author | Laguno, M. | |
dc.contributor.author | Von Wichmann, M. A. | |
dc.contributor.author | Van den Eynde, E. | |
dc.contributor.author | Navarro, J. | |
dc.contributor.author | Cifuentes, Carmen | |
dc.contributor.author | Murillas, J. | |
dc.contributor.author | Veloso, S. | |
dc.contributor.author | Martínez-Rebollar, M. | |
dc.contributor.author | Guardiola, J.M. | |
dc.contributor.author | Jou, A. | |
dc.contributor.author | Gómez-Sirvent, J.L. | |
dc.contributor.author | Cervantes, M. | |
dc.contributor.author | Pineda, J.A. | |
dc.contributor.author | López-Calvo, S. | |
dc.contributor.author | Carrero, Ana | |
dc.contributor.author | Montes, M.L. | |
dc.contributor.author | Deig, E. | |
dc.contributor.author | Tapiz, A. | |
dc.contributor.author | Ruiz-Mesa, J.D. | |
dc.contributor.author | Cruceta, A. | |
dc.contributor.author | de Lazzari, E. | |
dc.contributor.author | Mallolas, Josep | |
dc.date.accessioned | 2021-06-14T17:34:05Z | |
dc.date.available | 2021-06-14T17:34:05Z | |
dc.date.issued | 2016-12 | |
dc.identifier.citation | Laguno, M.; Von Wichmann, M. A.; Van den Eynde, E. [et al.]. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study. International Journal of Infectious Diseases, 2016, 53, p. 46-51. Disponible en: <https://www.sciencedirect.com/science/article/pii/S1201971216312127?via%3Dihub>. Fecha de acceso: 14 jun. 2021. DOI: 10.1016/j.ijid.2016.10.028 | ca |
dc.identifier.issn | 1201-9712 | ca |
dc.identifier.uri | http://hdl.handle.net/20.500.12328/2628 | |
dc.description.abstract | Introduction: Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC + pegylated interferon-α2a/ribavirin (PEG-IFN/RBV) in the retreatment of HIV–HCV co-infected patients with HCV genotype 1. Methods: This was a phase III prospective trial. HIV–HCV (genotype 1) co-infected patients from 16 hospitals in Spain were included. These patients received 4 weeks of PEG-IFN/RBV (lead-in), followed by response-guided therapy with PEG-IFN/RBV plus BOC (a fixed 44 weeks was indicated in the case of cirrhosis). The primary endpoint was the sustained virological response (SVR) rate at 24 weeks post-treatment. Efficacy and safety were evaluated in all patients who received at least one dose of the study drug. Results: From June 2013 to April 2014, 102 patients were enrolled, 98 of whom received at least one treatment dose. Seventy-three percent were male, 34% were cirrhotic, 23% had IL28b CC, 65% had genotype 1a, and 41% were previous null responders. The overall SVR rate was 67%. Previous null-responders and cirrhotic patients had lower SVR rates (57% and 51%, respectively). Seventy-six patients (78%) completed the therapy scheme; the most common reasons for discontinuation were lack of response at week 12 (12 patients) and adverse events (six patients). Conclusions: Response-guided therapy with BOC in combination with PEG-IFN/RBV led to an overall SVR rate of 67%, but an SVR rate of only 51% in patients with cirrhosis. The therapy was generally well tolerated. Although the current standards of care do not include BOC + PEG-IFN/RBV, the authors believe that this combination can be beneficial in situations where new HCV direct antiviral agent interferon-free therapies are not available yet. | en |
dc.format.extent | 6 | ca |
dc.language.iso | eng | ca |
dc.publisher | Elsevier | ca |
dc.relation.ispartof | International Journal of Infectious Diseases | ca |
dc.relation.ispartofseries | 53; | |
dc.rights | © 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-NDlicense (http://creativecommons.org/licenses/by-nc-nd/4.0/). | en |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject.other | Teràpia PEG-IFN | ca |
dc.subject.other | RBV + BOC | ca |
dc.subject.other | Pacients | ca |
dc.subject.other | VIH-VHC | ca |
dc.subject.other | Genotip 1 | ca |
dc.subject.other | Inhibidors orals | ca |
dc.subject.other | Hepatitis C | ca |
dc.subject.other | Boceprevir | ca |
dc.subject.other | Proteasa | ca |
dc.subject.other | Terapia PEG-IFN | es |
dc.subject.other | RBV + BOC | es |
dc.subject.other | Pacientes | es |
dc.subject.other | VIH-VHC | es |
dc.subject.other | Genotipo 1 | es |
dc.subject.other | Inhibidores orales | es |
dc.subject.other | Hepatitis C | es |
dc.subject.other | Boceprevir | es |
dc.subject.other | Peptidasas | es |
dc.subject.other | PEG-IFN therapy | en |
dc.subject.other | RBV + BOC | en |
dc.subject.other | Patients | en |
dc.subject.other | VIH-VHC | en |
dc.subject.other | Genotype 1 | en |
dc.subject.other | Oral inhibitors | en |
dc.subject.other | Hepatitis C | en |
dc.subject.other | Boceprevir | en |
dc.subject.other | Protease | en |
dc.title | Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study | en |
dc.type | info:eu-repo/semantics/article | ca |
dc.description.version | info:eu-repo/semantics/publishedVersion | ca |
dc.rights.accessLevel | info:eu-repo/semantics/openAccess | |
dc.embargo.terms | cap | ca |
dc.subject.udc | 61 | ca |
dc.subject.udc | 616.9 | ca |
dc.identifier.doi | https://dx.doi.org/10.1016/j.ijid.2016.10.028 | ca |